Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topiramato para el temblor esencial
Elisa Bruno, Alessandra Nicoletti, Graziella Quattrocchi, Roberta Allegra, Graziella Filippini, Carlo Colosimo, Mario Zappia | 14 abril 2017

Topics

Temas

Flowchart of the literature search on alprazolam and essential tremor.

Figuras y tablas -
Figure 1

Flowchart of the literature search on alprazolam and essential tremor.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figuras y tablas -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Figuras y tablas -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1: Comparison for efficacy, Outcome 1: Clinical rating scale

Figuras y tablas -
Analysis 1.1

Comparison 1: Comparison for efficacy, Outcome 1: Clinical rating scale

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings 1. Alprazolam for essential tremor

Alprazolam for essential tremor

Patient or population: patients with essential tremor
Settings: outpatients
Intervention: alprazolam

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Alprazolam

Tremor severity
Clinical rating scale. Scale from 0 to 4
Follow‐up: 2 weeks

Mean tremor severity in control groups was
2.13 points

Mean tremor severity in intervention group was
0.75 lower
(0.67 to 0.83 lower)

24
(1 study)

⊕⊝⊝⊝
Very lowa,b

Withdrawals due to adverse events

Follow‐up: 2 weeks

None

None

24

(1 study)

⊕⊝⊝⊝
Very lowa,b

Quality of life

Investigator global assessment

Scale from 1 to 7

Follow‐up: 2 weeks

Mean score in the control group was

3.83 points

Mean score in the intervention group was

1.16 lower

(0.17 to 2.15 lower)

24

(1 study)

⊕⊝⊝⊝
Very lowa,b

Quality of life

Investigator global assessment

Scale from 1 to 7

Follow‐up: 2 weeks

Mean score in the control group was

3.5points

Mean score in the intervention group was

0.67 lower

(0.27 to 1.61 lower)

24

(1 study)

⊕⊝⊝⊝
Very lowa,b

*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality: We are very uncertain about the estimate

aDowngraded by 2 levels for very serious risk of bias: allocation and blinding methods not described (selection bias); number of adverse events in the placebo group not reported (reporting bias); essential tremor diagnostic criteria applied to participants not reported; patient exclusion and inclusion criteria not specified. An arbitrary, not validated, clinical rating scale for tremor severity was used for assessment of tremor.
bDowngraded by 2 levels for very serious imprecision: small sample size; uncertainty of clinical relevance of results reported and of effects measured.

Figuras y tablas -
Summary of findings 1. Alprazolam for essential tremor
Ir a la tabla de la revisión
Comparison 1. Comparison for efficacy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1.1 Clinical rating scale Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.75 [‐0.83, ‐0.67]
Figuras y tablas -
Comparison 1. Comparison for efficacy
Ir a la tabla de la revisión